Prediction of Peritoneal Recurrence in Patients with Gastric Cancer: a Multicenter Study

Abstract

Purpose

The peritoneum is the common recurrence site of gastric cancer (GC) presenting with worse survival. Although some predictive clinicopathological factors have been identified, there is no comprehensive assessment of peritoneal recurrence risk prediction for patients treated with adjuvant chemotherapy (CR) or chemoradiotherapy (CRT) after surgery. We aimed to predict peritoneal recurrence and develop a new scoring model in GC.

Methods

This retrospective study included 274 GC patients who presented with recurrence after curative gastrectomy followed by adjuvant chemotherapy (CT) or chemoradiotherapy (CRT). Risk factors for peritoneal recurrence were analyzed using the following parameters: age, gender, tumor location and characteristics, and differences between treatment modalities. All parameters were assessed by binary logistic regression analysis to compare the patients with and without peritoneal recurrence. Then, a new risk scoring model was developed.

Results

Peritoneal recurrence was observed in 115 (44.1%) patients. Peritoneal recurrence was higher in female gender (odds ratio (OR), 1.93; 1.07–3.49, P = 0.030, 1 point), T4a-b stage (OR, 2.47; 1.14–5.36, P = 0.022, 1 point), poor/undifferentiated (OR, 2.04; 1.31–4.06, P = 0.004, 1 point), and signet cell carcinoma (OR, 2.04; 1.04–4.02, P = 0.038, 1 point) after adjusted for resection and dissection types. The risk scoring model was developed using the related parameters: Peritoneal recurrence rates were 24.6%, 42.6%, and 71.4% for group 1 (0 point), group 2 (1–2 points), and group 3 (3–4 points), respectively.

Conclusion

Female gender, T4 tumor stage, undifferentiated histopathology, and signet cell type had a tendency to peritoneal recurrence after adjusted for treatment modalities. Patients with 3 or 4 risk factors had an 8.8-fold increased risk for the development of peritoneal recurrence.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  Google Scholar 

  2. 2.

    Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7:52307–16.

    Article  Google Scholar 

  3. 3.

    Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33.

    CAS  Article  Google Scholar 

  4. 4.

    Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.

    CAS  Article  Google Scholar 

  5. 5.

    Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–42.

    CAS  Article  Google Scholar 

  6. 6.

    Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, et al. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol. 2012;104:367–73.

    Article  Google Scholar 

  7. 7.

    Yang W, Hu R, Li GC, Zhou ML, Wang Y, Shen LJ, et al. Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study. Br J Radiol. 2018;91:20170594.

    Article  Google Scholar 

  8. 8.

    Ahmed A, Ukwenya AY, Makama JG. Mohammad I management and outcome of gastric carcinoma in Zaria. Nigeria Afr Health Sci. 2011;11:353–61.

    CAS  PubMed  Google Scholar 

  9. 9.

    Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87:353–7.

    CAS  Article  Google Scholar 

  10. 10.

    Lee JH, Son SY, Lee CM, Ahn SH, Park DJ, Kim HH. Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy. Gastric Cancer. 2014;17:529–36.

    CAS  Article  Google Scholar 

  11. 11.

    Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990;19:1357–62.

    CAS  Article  Google Scholar 

  12. 12.

    Burke EC, Karpeh MS Jr, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol. 1998;5:411–5.

    CAS  Article  Google Scholar 

  13. 13.

    D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808–16.

    Article  Google Scholar 

  14. 14.

    Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. World J Gastroenterol. 2014;20:5679–84.

    Article  Google Scholar 

  15. 15.

    Wei Y, Wang T, Song H, Tian L, Lyu G, Zhao L, et al. C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy. J Surg Res. 2017;211:266–78.

    CAS  Article  Google Scholar 

  16. 16.

    Shi C, Yang B, Chen Q, Yang J, Fan N. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer. Oncology. 2011;80:289–95.

    CAS  Article  Google Scholar 

  17. 17.

    Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, et al. ; Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206–2. Gastric Cancer. 2011;14:212–8.

  18. 18.

    Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14:2702–13.

    Article  Google Scholar 

  19. 19.

    Huang JY, Xu YY, Sun Z, Zhu Z, Song YX, Guo PT, et al. Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:4379–85.

    Article  Google Scholar 

  20. 20.

    Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526.

    CAS  Article  Google Scholar 

  21. 21.

    Mi DH, Li Z, Yang KH, Cao N, Lethaby A, Tian JH, et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperth. 2013;29:156–67.

    CAS  Article  Google Scholar 

  22. 22.

    Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622–8.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tulay Kus.

Ethics declarations

Ethical approval

This study was approved by the Institutional Ethics Committee and conducted in compliance with the ethical principles according to the Declaration of Helsinki

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kus, T., Kose, F., Aktas, G. et al. Prediction of Peritoneal Recurrence in Patients with Gastric Cancer: a Multicenter Study. J Gastrointest Canc (2020). https://doi.org/10.1007/s12029-020-00419-7

Download citation

Keywords

  • Gastric cancer
  • Peritoneal recurrence
  • Chemoradiotherapy
  • Chemotherapy
  • Prediction